View in EDS HTML Full Text PDF Full Text

Pharmacoeconomic evaluation of first-line tislelizumab for extensive-stage small cell lung cancer using a comparative validation of traditional survival and machine learning models.

Saved in:
Bibliographic Details
Title: Pharmacoeconomic evaluation of first-line tislelizumab for extensive-stage small cell lung cancer using a comparative validation of traditional survival and machine learning models.
Authors: Li Y; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China., Zou Y; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China., Liang C; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China., Feng Z; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China., Lu S; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China., Wang G; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China., Meng G; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China.
Source: Frontiers in public health [Front Public Health] 2026 Jun 17; Vol. 14, pp. 1841510. Date of Electronic Publication: 2026 Jun 17 (Print Publication: 2026).
Publication Type: Journal Article; Comparative Study
Journal Info: Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42388757
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pharmacoeconomic evaluation of first-line tislelizumab for extensive-stage small cell lung cancer using a comparative validation of traditional survival and machine learning models.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Li+Y%22">Li Y</searchLink>; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China.<br /><searchLink fieldCode="AU" term="%22Zou+Y%22">Zou Y</searchLink>; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China.<br /><searchLink fieldCode="AU" term="%22Liang+C%22">Liang C</searchLink>; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China.<br /><searchLink fieldCode="AU" term="%22Feng+Z%22">Feng Z</searchLink>; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China.<br /><searchLink fieldCode="AU" term="%22Lu+S%22">Lu S</searchLink>; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China.<br /><searchLink fieldCode="AU" term="%22Wang+G%22">Wang G</searchLink>; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China.<br /><searchLink fieldCode="AU" term="%22Meng+G%22">Meng G</searchLink>; Department of pharmacy, The First People's Hospital of Yulin, Guangxi, Yulin, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101616579%22">Frontiers in public health</searchLink> [Front Public Health] 2026 Jun 17; Vol. 14, pp. 1841510. <i>Date of Electronic Publication: </i>2026 Jun 17 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Comparative Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Editorial+Office%22">Frontiers Editorial Office </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101616579 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2296-2565 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222962565%22">22962565 </searchLink><i>NLM ISO Abbreviation: </i>Front Public Health <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42388757
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fpubh.2026.1841510
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1841510
    Titles:
      – TitleFull: Pharmacoeconomic evaluation of first-line tislelizumab for extensive-stage small cell lung cancer using a comparative validation of traditional survival and machine learning models.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Li Y
      – PersonEntity:
          Name:
            NameFull: Zou Y
      – PersonEntity:
          Name:
            NameFull: Liang C
      – PersonEntity:
          Name:
            NameFull: Feng Z
      – PersonEntity:
          Name:
            NameFull: Lu S
      – PersonEntity:
          Name:
            NameFull: Wang G
      – PersonEntity:
          Name:
            NameFull: Meng G
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 17
              M: 06
              Text: 2026 Jun 17
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2296-2565
          Numbering:
            – Type: volume
              Value: 14
          Titles:
            – TitleFull: Frontiers in public health
              Type: main
ResultId 1